Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments | Business Wire

May 11, 2021

Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments | Business Wire

Accelerated Biosciences’ ethically sourced human trophoblast stem cells (hTSCs) solve challenges for cancer-targeting therapies and regenerative medicine – offering pluripotency, immune-privilege, stability, and scalability without compromises. New data generated by Pluristyx scientists demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSC).